Roxadustat Versus Erythropoietin for Anemia Treatment in Diabetic Nephropathy.
Main Article Content
Abstract
Objective: To compare Roxadustat and Erythropoietin in improving haemoglobin levels among patients with diabetic nephropathy.
Methodology: This comparative observational study was conducted in the Department of Nephrology, Sheikh Zayed Hospital, Lahore. Sixty-four patients aged 18–75 years with diabetic nephropathy, chronic kidney disease, and anaemia were enrolled. Patients were allocated into two equal groups by the lottery method. Group A received Roxadustat 100 mg orally three times per week. Group B received erythropoietin 4000 IU subcutaneously twice weekly. Follow-up was three months. Data were analysed in SPSS version 27.0. A p-value of ≤0.05 was taken as significant.
Results: Baseline characteristics were similar between groups. Post-treatment haemoglobin was better among patients of Roxadustat group than in the group of erythropoietin (10.54 ± 1.75 vs 9.05 ± 2.17 g/dL). Mean haemoglobin rise was also greater (1.97 ± 1.21 vs 0.98 ± 1.87 g/dL). Haemoglobin response was higher with Roxadustat (78.1% vs 40.6%). Roxadustat was an independent predictor of haemoglobin response (adjusted OR 6.41, 95% CI 1.86–22.07; p=0.003).
Conclusion: We found Roxadustat more effective than erythropoietin for improving haemoglobin in anaemic patients with diabetic nephropathy.
Keywords: Anaemia; Diabetic nephropathy; Erythropoietin; Haemoglobin; Roxadustat.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal of Muhammad Medical College (J Muhammad Med Coll) belief that all researches are basically conducted for the benefit of humanity. Research is the product of an investment by society and consequently its fruits should be returned in a transparent fashion to all humankind without any discrimination.
Journal of Muhammad Medical College (JMMC) is an open access journal. All content is freely available immediately upon publication, without charge to the user or their institution. Users are permitted to read, download, copy, distribute, print, search, link to the full text, or otherwise use the content for any lawful purpose, including commercial use, provided the original author(s) and JMMC are properly credited. Articles are published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0):
Authors retain copyright of their work and grant JMMC the right of first publication. No separate copyright transfer or assignment is required.
